Candon, D. et al. 2014. Modelling the cost-effectiveness of adjuvant lapatinib for early-stage breast cancer. Acta Oncologica. 53, 2 (Feb. 2014), 201–208. DOI:https://doi.org/10.3109/0284186X.2013.840740.